“clostridium-difficile” Archives

in
Entry Author Date Location
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More 05/08/20 National
Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory 04/23/20 Boston
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) 04/22/20 National
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy 01/08/20 San Francisco
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome 06/26/19 Boulder/Denver
With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease 06/10/19 Boston
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes 05/30/19 San Francisco
Kaleido Bio Downsizes IPO, Raises $75M for Microbiome Drug Tests 02/27/19 Boston
Gates Foundation, Bristol-Myers Join $27M Funding for Vedanta Bio 12/24/18 Boston
Xenex Adds $4.8M for Hospital Trial Program of Germ-Zapping Robots 10/09/18 Texas
With FDA’s Blessing, Seres Preps New “Pivotal” Microbiome Drug Trial 03/16/17 Boston
Xenex Gets $38M From Essex Woodlands, Others for Germ-Zapping Robots 02/24/17 Texas
Seres Dissects Failed Microbiome Drug Trial, Suggests Changes to FDA 01/31/17 Boston
U-M Gets $2M to Study Xenex Robots’ Ability to Sanitize Hospitals 01/12/17 Texas
Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More 07/29/16 National
In a Microbiome Setback, Seres Drug Fails in Phase 2, Shares Crushed 07/29/16 Boston
With Bugs As Drugs, Evelo CEO Plans Immune, Cancer Trials in 2017 07/12/16 Boston
Vedanta Nabs $50M To Expand Microbiome Into Immune-Boosting Therapies 06/06/16 Boston
From Adviser to CEO: Morris Miller on Xenex’s Disinfecting Robots 11/25/15 Texas
Five Takeaways From “Boston’s Life Science Disruptors” 10/02/15 Boston
Bon Appetit: Seres And Its Microbiome Gut Treatment Notch $134M IPO 06/25/15 Boston
Gold Bugs? Seres Files For First IPO of Human Microbiome Era 05/27/15 Boston
One Week Into The New Year, Five Biotechs Reel in $220M Venture Cash 01/08/15 National
Don’t Get Comfortable: 5 Biopharma Flashpoints to Consider in 2015 01/06/15 National
Independent No More: Cubist Sold to Merck for $9.5B 12/08/14 Boston
With Crossover Cash, Seres Health Aims For Big Microbiome Milestones 12/02/14 Boston
Ebola Outbreak a Proving Ground for Lucigen’s Rapid Diagnostic 11/03/14 Wisconsin
Cubist CEO Bonney Steps Down After 12-Year Stint 10/20/14 Boston
J&J Immunology Exec on Investing at the Crossroads of the Microbiome 07/24/14 National
Page 1 of 2 next page »